Quest Partners LLC Has $29,000 Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Quest Partners LLC lifted its position in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 3,310.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,206 shares of the biotechnology company’s stock after purchasing an additional 3,112 shares during the quarter. Quest Partners LLC’s holdings in Astria Therapeutics were worth $29,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ameritas Investment Partners Inc. raised its stake in shares of Astria Therapeutics by 135.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after buying an additional 2,861 shares in the last quarter. Panagora Asset Management Inc. bought a new stake in Astria Therapeutics in the fourth quarter valued at about $119,000. Price T Rowe Associates Inc. MD bought a new stake in Astria Therapeutics in the first quarter valued at about $200,000. American International Group Inc. raised its position in Astria Therapeutics by 49.4% in the first quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company’s stock worth $346,000 after purchasing an additional 8,122 shares in the last quarter. Finally, Trexquant Investment LP bought a new position in Astria Therapeutics during the fourth quarter worth about $409,000. 98.98% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ATXS has been the subject of a number of recent research reports. Oppenheimer increased their target price on Astria Therapeutics from $25.00 to $26.00 and gave the stock an “outperform” rating in a report on Tuesday, August 13th. Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Wedbush reiterated an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a research report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Finally, TD Cowen initiated coverage on shares of Astria Therapeutics in a report on Monday, July 29th. They set a “buy” rating and a $35.00 price objective for the company. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Astria Therapeutics currently has an average rating of “Buy” and an average target price of $25.20.

Astria Therapeutics Stock Up 2.4 %

Shares of NASDAQ ATXS opened at $12.65 on Friday. Astria Therapeutics, Inc. has a 12-month low of $4.26 and a 12-month high of $16.90. The firm’s 50-day simple moving average is $11.30 and its 200 day simple moving average is $10.97. The company has a market cap of $694.65 million, a price-to-earnings ratio of -5.56 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS) last announced its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). On average, equities analysts expect that Astria Therapeutics, Inc. will post -1.66 earnings per share for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.